Mount Sinai and King Saud University Launch Three-Year Precision Medicine Initiative for Familial IBD
核心洞察
Mount Sinai (搜索) and King Saud University Medical City announced a three-year collaboration to study familial inflammatory bowel disease (搜索) patterns in Saudi families with multiple affected members.
The initiative will collect biospecimens and clinical data to identify exposure and biological markers that drive IBD (搜索) disease mechanisms and outcomes in high-risk families.
Researchers aim to accelerate development of personalized diagnostics and therapies by combining multi-omics profiling with detailed family pedigrees and clinical histories.
Mount Sinai (搜索) and King Saud University Medical City in Riyadh, Saudi Arabia, have announced a three-year collaboration aimed at advancing precision medicine for familial inflammatory bowel disease (搜索) (IBD (搜索)). The partnership will focus on Saudi families with multiple members affected by IBD, including Crohn's disease (搜索) and ulcerative colitis (搜索), to identify biological markers that could lead to earlier diagnosis and more personalized treatment options.
Research Framework and Methodology
The collaboration is designed to create a unique resource combining high-quality biospecimens with detailed clinical information and family pedigrees. King Saud University Medical City will identify and enroll eligible participants, collecting whole blood, serum, and stool samples alongside de-identified health and family history information from individuals with IBD (搜索) and relatives at increased risk. Mount Sinai (搜索) will lead advanced biomarker discovery and integrative analyses using multi-omics profiling and other state-of-the-art research tools.
"Familial IBD (搜索) is still poorly understood, even though families with several affected members can teach us a great deal about how these diseases develop," says Jean-Frédéric Colombel, MD, Professor of Medicine (Gastroenterology) and Director of the Susan and Leonard Feinstein Inflammatory Bowel Disease (搜索) Clinical Center at the Icahn School of Medicine at Mount Sinai. "What makes this collaboration exciting is the ability to study well-characterized families alongside comprehensive molecular data. That combination is rare, and it gives us a real chance to pinpoint early signals of disease."
Immune System Insights Through Familial Studies
The research approach leverages the unique opportunity that familial IBD (搜索) provides to study immune system interactions between genetics and environment. When multiple family members are affected, researchers can track how immune signals change over time and investigate why some relatives develop disease while others remain unaffected.
"Familial IBD (搜索) gives us a rare opportunity to study the immune system in a context where genetics and environment are clearly interacting," says Miriam Merad, MD, PhD, Chair of Immunology and Immunotherapy and Director of the Marc and Jennifer Lipschultz Precision Immunology Institute at the Icahn School of Medicine at Mount Sinai. "When several people in the same family are affected, we can follow how immune signals shift over time and begin to understand why some relatives develop disease while others do not."
Clinical Impact and Patient Benefits
For families living with IBD (搜索), the uncertainty surrounding disease risk can persist for years, particularly for relatives concerned about their own susceptibility. The collaboration aims to address this challenge by recognizing earlier patterns of risk and disease activity through careful family monitoring linked with high-quality biospecimens.
"For families living with IBD (搜索), uncertainty can last for years—especially for relatives who worry they may be next," says Nahla Azzam, MD, Professor of Medicine at King Saud University and IBD consultant at King Saud University Medical City. "Familial clustering gives us a valuable opportunity to recognize earlier patterns of risk and disease activity. By following families carefully and linking clinical histories with high-quality biospecimens, we hope to shorten the time to diagnosis and guide treatment choices with greater confidence and better outcomes."
Global Health Context and Future Implications
The collaboration addresses the urgent need for precision medicine approaches as inflammatory bowel disease (搜索) continues to increase worldwide at an unprecedented pace, closely tracking major environmental and lifestyle changes. The research aims to move beyond one-size-fits-all treatment models toward diagnostics and therapies that meet patients' individual needs.
"This collaboration reflects our commitment to building a discovery platform that translates rigorous clinical data into actionable precision medicine," says Abdurahman Niazy, PhD, Director of the Prince Naif Bin Abdulaziz Health Research Center (搜索), the research arm of King Saud University Medical City. "By combining KSUMC's ability to identify and characterize high-risk familial cohorts with Mount Sinai (搜索)'s advanced multi-omics and integrative biomarker discovery capabilities, we aim to define clearer biological signals that support earlier risk assessment and more precise, individualized treatment strategies—first for families in Saudi Arabia, and ultimately for patients worldwide."
Implementation and Future Directions
Operational next steps include finalizing cohort size, visit schedule, and logistics for regulatory approvals, sample handling, and data transfer. After the initial three-year term, Mount Sinai (搜索) and King Saud University Medical City may consider extending the collaboration to pursue promising discoveries into translational studies.
Manasi Agrawal, MD, MS, inaugural Director of Environmental Gastroenterology in the Henry D. Janowitz Division of Gastroenterology at Mount Sinai (搜索), emphasizes the collaborative approach: "By combining rigorous clinical and biomarker data, deep scientific expertise, and a common focus on the lived experiences of families affected by IBD (搜索), we are creating opportunities for discovery that would not be possible independently. Together, we are laying the groundwork to uncover clearer biological signals and to chart a path toward earlier diagnosis and more effective, personalized treatment strategies—and, ultimately, enabling IBD prevention and risk mitigation."